Description

Paclimedak Concentrate for Infusions 6 mg/ml. 16.7 ml. (100 mg.) №1

Ingredients:

Each ml contains 6 mg of Paclitaxel. Other ingredients include ethanol, polyoxy 35 castor oil, and citric acid.

Dosage:

The recommended dosage of Paclimedak concentrate for infusions is determined by the patient’s body surface area and the specific protocol used. It is administered intravenously by a healthcare professional.

Indications:

Paclimedak is indicated for the treatment of various cancers including breast cancer, lung cancer, and ovarian cancer. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications:

Do not use Paclimedak if you are allergic to paclitaxel or any of the ingredients in the formulation. It is important to inform your healthcare provider about any allergies or medical conditions before starting treatment.

Directions:

Paclimedak should only be administered by a healthcare professional in a clinical setting. The infusion duration and dosage will be determined by your healthcare provider based on your individual condition.

Scientific Evidence:

Studies have shown that Paclimedak is effective in the treatment of various types of cancer. Research published in the Journal of Clinical Oncology demonstrated the efficacy of paclitaxel-based regimens in improving survival rates in patients with advanced breast cancer.

Additional Information:

It is important to monitor for potential side effects such as allergic reactions, low blood cell counts, and nerve damage during treatment with Paclimedak. Your healthcare provider will closely monitor you for any adverse reactions.

Pharmacological Effects: Paclimedak works by disrupting the microtubule structures in cancer cells, thereby inhibiting cell division and growth. This mechanism of action makes it effective in slowing down the progression of cancer.

Clinical Trials: Clinical trials have shown that Paclimedak, when used in combination with other chemotherapy agents, can significantly improve response rates and overall survival in cancer patients. A study published in the New England Journal of Medicine reported positive outcomes in patients with advanced ovarian cancer treated with paclitaxel-based regimens.